Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 284

1.

Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study.

Nadeem K, Colantonio D, Kircanski I, Naqvi A, Hitzler J, Whitlock JA, Dupuis LL.

Pediatr Blood Cancer. 2019 Oct 18:e28044. doi: 10.1002/pbc.28044. [Epub ahead of print]

PMID:
31625674
2.

Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.

August KJ, Farooki S, Fulbright JM, August A, Portnoy JM, Pommert L, Burke MJ, Guest EM.

Pediatr Blood Cancer. 2019 Oct 1:e28021. doi: 10.1002/pbc.28021. [Epub ahead of print]

PMID:
31571395
3.

FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults.

Li RJ, Jin R, Liu C, Cao X, Manning ML, Di XM, Przepiorka D, Namuswe F, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2019 Aug 23. doi: 10.1158/1078-0432.CCR-19-1255. [Epub ahead of print]

PMID:
31444252
4.

Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis.

Kamal N, Koh C, Samala N, Fontana RJ, Stolz A, Durazo F, Hayashi PH, Phillips E, Wang T, Hoofnagle JH; Drug-Induced Liver Injury Network.

Hepatol Int. 2019 Sep;13(5):641-648. doi: 10.1007/s12072-019-09971-2. Epub 2019 Aug 7.

PMID:
31392570
5.
6.

Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge.

Liu Y, Smith CA, Panetta JC, Yang W, Thompson LE, Counts JP, Molinelli AR, Pei D, Kornegay NM, Crews KR, Swanson H, Cheng C, Karol SE, Evans WE, Inaba H, Pui CH, Jeha S, Relling MV.

J Clin Oncol. 2019 Aug 10;37(23):2051-2061. doi: 10.1200/JCO.18.02439. Epub 2019 Jun 12.

PMID:
31188727
7.

Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase.

Faschinger AM, Sessler N.

Adv Ther. 2019 Aug;36(8):2106-2121. doi: 10.1007/s12325-019-00988-5. Epub 2019 May 28.

PMID:
31140125
8.

Clinical efficacy of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) in the initial treatment of advanced stage (stage III-IV) extranodal NK/T-cell lymphoma, and its correlation with Epstein-Barr virus.

Zhao Q, Fan S, Chang Y, Liu X, Li W, Ma Q, Li Y, Wang Y, Zhang L, Zhang M.

Cancer Manag Res. 2019 Apr 24;11:3555-3564. doi: 10.2147/CMAR.S191929. eCollection 2019.

9.

A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage.

Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, Jasty Rao R, Slagle L, Bishop L, Pettit K, Bixby DL, Burke PW, Perissinotti AJ.

Leuk Lymphoma. 2019 May 17:1-15. doi: 10.1080/10428194.2019.1608530. [Epub ahead of print]

PMID:
31099289
10.

Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions.

Cooper SL, Young DJ, Bowen CJ, Arwood NM, Poggi SG, Brown PA.

Pediatr Blood Cancer. 2019 Aug;66(8):e27797. doi: 10.1002/pbc.27797. Epub 2019 May 16.

PMID:
31099154
11.

Correction to: Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

Heo YA, Syed YY, Keam SJ.

Drugs. 2019 Jun;79(8):901. doi: 10.1007/s40265-019-01137-6.

12.

Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

Heo YA, Syed YY, Keam SJ.

Drugs. 2019 May;79(7):767-777. doi: 10.1007/s40265-019-01120-1. Erratum in: Drugs. 2019 May 17;:.

13.

Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management.

Bade NA, Lu C, Patzke CL, Baer MR, Duong VH, Law JY, Lee ST, Sausville EA, Zimrin AB, Duffy AP, Lawson J, Emadi A.

J Oncol Pharm Pract. 2019 Mar 27:1078155219838316. doi: 10.1177/1078155219838316. [Epub ahead of print]

PMID:
30917738
14.

Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia.

Lau KM, Saunders IM, Goodman A.

J Oncol Pharm Pract. 2019 Mar 1:1078155219833438. doi: 10.1177/1078155219833438. [Epub ahead of print]

PMID:
30823860
15.

[Effectiveness of P-Gemox chemotherapy combined with radiotherapy in newly diagnosed,stage ⅠE to ⅡE, extranodal nasal type natural killer/T-cell lymphoma].

Ji J, Li L, She NN, Liu XH, Long Y, Zhang XB.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Feb 5;33(2):132-137. doi: 10.13201/j.issn.1001-1781.2019.02.010. Chinese.

PMID:
30808138
16.

Novel site-specific PEGylated L-asparaginase.

Meneguetti GP, Santos JHPM, Obreque KMT, Barbosa CMV, Monteiro G, Farsky SHP, Marim de Oliveira A, Angeli CB, Palmisano G, Ventura SPM, Pessoa-Junior A, de Oliveira Rangel-Yagui C.

PLoS One. 2019 Feb 12;14(2):e0211951. doi: 10.1371/journal.pone.0211951. eCollection 2019.

17.

Chronic active EBV infection associated with NK cell lymphoma and hemophagocytic lymphohistiocytosis in a 27-year-old woman: A case report.

Wang YD, Wu LL, Ma LY, Shang XB, Li ZY, Wang W, Shen C, Yang JJ, Sun LX, Zhao CY.

Medicine (Baltimore). 2019 Jan;98(2):e14032. doi: 10.1097/MD.0000000000014032.

18.

Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4.

Schore RJ, Devidas M, Bleyer A, Reaman GH, Winick N, Loh ML, Raetz EA, Carroll WL, Hunger SP, Angiolillo AL.

Leuk Lymphoma. 2019 Jul;60(7):1740-1748. doi: 10.1080/10428194.2018.1542146. Epub 2019 Jan 10.

PMID:
30626253
19.

Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity.

Vyas C, Jain S, Kapoor G, Mehta A, Takkar Chugh P.

Pediatr Hematol Oncol. 2018 Aug - Sep;35(5-6):331-340. doi: 10.1080/08880018.2018.1538277. Epub 2018 Nov 29.

PMID:
30488741
20.

Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study.

Liu T, Zhu F, Xiao Y, Li Q, Liu X, Yang K, Wu G, Zhang L.

Cancer Manag Res. 2018 Oct 29;10:5061-5069. doi: 10.2147/CMAR.S179567. eCollection 2018.

Supplemental Content

Loading ...
Support Center